A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | MicrobiomeTrials
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-23Est. Completion: 2030-12
Enrollment target: 325 participants
Locations
University of Southern California /ID# 272414, Los Angeles, California, United States
Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven, Connecticut, United States
Dana-Farber Cancer Institute /ID# 271846, Boston, Massachusetts, United States
University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor, Michigan, United States
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York, New York, United States
University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill, North Carolina, United States
Atrium Health Levine Cancer Institute /ID# 271510, Charlotte, North Carolina, United States
Wake Forest Baptist Health /ID# 271294, Winston-Salem, North Carolina, United States
Oregon Health and Science University /ID# 272282, Portland, Oregon, United States
University of Texas - Southwestern Medical Center /ID# 271914, Dallas, Texas, United States
Huntsman Cancer Institute /ID# 271618, Salt Lake City, Utah, United States
Northwest Medical Specialties Tacoma /ID# 272506, Tacoma, Washington, United States
Liverpool Hospital /ID# 272002, Liverpool, New South Wales, Australia
Other microbiome trials you might be interested in